The influence of beta2-receptor polymorphisms on Recovery of Heart failure (REHAB)

• Conditions: Congestive heart failure; systolic heart failure; 10019280

• Registration Number: NL-OMON31894
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

Recovered gruop: Patients with systolic heart failure who initially had a LVEF < 45% and who reached a LVEF * 45% after a minimum treatment period of 1.5 years will be included.
Patients must be over 18 years of age and competent of giving informed consent.;Control group: Patients with heart failure who have had an initial LVEF <45% and have not recovered (a LVEF < 45%) after a minimum treatment period of 1.5 year will serve as controls.
Controls must be over 18 years of age and competent of giving informed consent

Exclusion Criteria

1. Diastolic heart failure
2. Congenital causes of heart failure

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. The difference in occurrence of beta2-receptor haplotypes between the<br /><br>recovered and the control group will serve as a primary outcome.<br /><br>2. The difference in occurrence of beta2-receptor haplotypes in a good<br /><br>responders group versus a bad responders group. Good responders will be defined<br /><br>as a change in LVEF >15% and bad responders as a change in LVEF <15%, both<br /><br>after an average treatment of 1.5 years.<br /><br>3. The difference in mean change LVEF in each group of beta2-receptor<br /><br>haplotypes.<br /><br>4. All outcomes described above, but then assessed for the single-nucleotide<br /><br>polymorphisms.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>